C-reactive protein and risk of cognitive decline: The REGARDS study

Miguel Arce Rentería, Sarah R. Gillett, Leslie A. McClure, Virginia G. Wadley, Stephen P. Glasser, Virginia J. Howard, Brett M. Kissela, Frederick W. Unverzagt, Nancy S. Jenny†, Jennifer J. Manly, Mary Cushman

1 Department of Neurology, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University College of Physicians and Surgeons, New York, New York, United States of America, 2 Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont, United States of America, 3 Departments of Epidemiology and Biostatistics, Drexel University, Philadelphia, Pennsylvania, United States of America, 4 Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 5 Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 6 Department of Neurology and Rehabilitation Medicine at the University of Cincinnati, Cincinnati, Ohio, United States of America, 7 Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 8 Department of Pathology & Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont, United States of America, 9 Departments of Medicine and Pathology & Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont, United States of America

† Deceased.
* mary.cushman@uvm.edu

Abstract

Markers of systemic inflammation are associated with increased risk of cognitive impairment, but it is unclear if they are associated with a faster rate of cognitive decline and whether this relationship differs by race. Our objective was to examine the association of baseline C-reactive protein (CRP) with cognitive decline among a large racially diverse cohort of older adults. Participants included 21,782 adults aged 45 and older (36% were Black, mean age at baseline 64) from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. CRP was measured at baseline and used as a continuous variable or a dichotomous grouping based on race-specific 90th percentile cutoffs. Cognitive measures of memory and verbal fluency were administered every 2 years for up to 12 years. Latent growth curve models evaluated the association of CRP on cognitive trajectories, adjusting for relevant demographic and health factors. We found that higher CRP was associated with worse memory (B = -.039, 95% CI [-.065, -.014]) and verbal fluency at baseline (B = -.195, 95% CI [-.219, -.170]), but not with rate of cognitive decline. After covariate adjustment, the association of CRP on memory was attenuated (B = -.005, 95% CI [-.031, -.021]). The association with verbal fluency at baseline, but not over time, remained (B = -.042, 95% CI [-.067, -.017]). Race did not modify the association between CRP and cognition. Findings suggest that levels of CRP at age 45+, are a marker of cognitive impairment but may not be suitable for risk prediction for cognitive decline.
1. Introduction

As global population aging increases, the prevalence of cognitive impairment and neurocognitive disorders, such as Alzheimer’s disease and related disorders, will increase dramatically [1, 2]. Higher prevalence of cognitive impairment among aging adults is a public health concern, as it is associated with increased rates of disability [3], larger health care costs [4], and increase risk of dementia [5]. As such, identification of those at highest risk for cognitive decline might allow targeted prevention efforts.

Inflammation may be an important mechanism underlying risk for cognitive impairment and dementia [6–8]. C-reactive protein (CRP) is a marker of acute inflammation in acute illness, but low level inflammation in healthy people is captured by high sensitivity assays and is related to a variety of disease outcomes [9]. A number of studies suggest that CRP might be associated with cognitive impairment [10–13], with some evidence of increased risk of cognitive decline [14–16]. While some prospective studies have found higher rates of cognitive decline among individuals with higher CRP [17–19], the majority of these studies were among highly selected clinic or cohort samples of adults. In order to generalize the relationship between CRP and cognitive outcomes, a national, longitudinal, population-based sample of adults is needed.

Associations between CRP and cognitive decline may be moderated by race. Generally, Black Americans are at higher risk of cognitive impairment compared to White Americans [20, 21]. Similarly, they have higher levels of CRP than their White counterparts [22–24]. There is some evidence to suggest that Black people may respond to inflammatory stimuli differently than White people [25, 26]. Gene variants that up-regulate proinflammatory cytokines are also more common in Black than White Americans [26]. Given these findings, it can be hypothesized that Black Americans may be at higher risk for inflammation-related cognitive decline.

The objective of this study was to examine the association between CRP and cognitive trajectories in a national, population-based cohort of Black and White American adults. We hypothesized that higher baseline CRP concentration would be associated with worse cognitive functioning at baseline and a steeper rate of cognitive decline over time, independent of other risk factors. Additionally, we evaluated whether any association of CRP with cognition would be moderated by race such that the association would be stronger among Black compared to White people.

2. Methods

2.1. Design and procedures

The REasons for Geographical and Racial Differences in Stroke (REGARDS) study is a national, population-based prospective cohort study of Black and White Americans aged ≥45 years at baseline [27]. The cohort includes 30,239 participants, 45% men and 55% women, 58% White and 42% Black, 56% residing in the southeastern Stroke Belt region of United States (Alabama, Arkansas, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, and Tennessee) and 44% in the remaining 40 contiguous United States. The Stroke Belt region has well-documented higher rates of stroke than the rest of the United States [28]. Participants were recruited from commercially available lists of U.S. residents using mail and telephone contact. Enrollment occurred between January 2003 and October 2007. Interviewers were trained to identify participants answering questions in a manner suggesting lack of comprehension, and such participants were not included further. Baseline demographic information, medical history, and health status were collected by computer-assisted telephone interview (CATI) with follow-ups occurring every 6 months (maximum follow-up to 12 years). Trained health care professionals collected blood and urine samples, electrocardiogram, blood pressure, height, and weight.
during an in-home visit at baseline. Further methodological details are available elsewhere [27], but in brief, blood pressure quality control was monitored by central examination of digit preference, height was measured once utilizing an 8-foot metal tape measure and a square, and weight (without shoes) was measured once using a standard 300-lb calibrated scale.

As shown in Fig 1, for the current project, participants were excluded if they reported a history of stroke at baseline, cognitive impairment at baseline based on the Six Item Screener (SIS score \( \leq 4 \)) [29], or if missing CRP data. The resulting sample size for analysis was 21,782.

REGARDS was approved by Institutional Review Boards of all participating institutions and all participants provided written informed consent. Potential participants who were able to respond to telephone questions provided verbal consent, which was followed by written consent at an in-home visit. The current study was approved by the Institutional Review Boards of Columbia University Medical Center and Larner College of Medicine at the University of Vermont.

2.2. Inflammatory biomarkers and laboratory analysis

At the in-home visit, blood was collected by trained personnel using standardized procedures after a 10–12 hour fast and centrifuged within 2 hours of collection. Plasma and serum were separated and shipped overnight on gel ice packs to a central laboratory. Samples were re-centrifuged and stored for batch processing [27]. Lipid profile and glucose were measured using the Ortho Vitros Clinical Chemistry System 950IRC instrument. CRP was measured in plasma with a high-sensitivity, particle enhanced immunonephelometric assay (N High Sensitivity CRP, Dade Behring Inc., Deerfield, IL; interassay CVs 2.1–5.7%). Validity of results using this blood collection method was confirmed using a paired samples technique [30] and the assay has reasonable within person variability [31]. In addition to evaluating CRP as a continuous

![Flow diagram for identifying participants](https://doi.org/10.1371/journal.pone.0244612.g001)
variable (with log transformation to correct for skewness), all participants were categorized as having either having CRP “above” or “below” race-specific 90th percentile cutoffs (≥ 8 mg/L for White adults and ≥ 12.3 mg/L for Black adults). Although studies suggest that a CRP ≥ 3 mg/L indicates levels of inflammation important to disease risk prediction [32, 33], we chose a race-specific higher cutoff for elevated CRP because differences in CRP are partially driven by genetic ancestry, and those with African ancestry have higher values than all other groups, suggesting that a single threshold value may not be appropriate [22]. CRP ≥ 3 mg/L was also not associated with risk of future stroke in Black Americans [34]. We chose race-specific 90th percentile in order to select the highest possible range of CRP for given racial group.

2.3. Cognitive assessment

Starting in 2006 and repeated every two years, participants completed cognitive measures over the phone administered by trained interviewers [35]. The cognitive measures assessed the cognitive domains of memory and verbal fluency/executive functioning. Episodic memory was assessed through the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) Word List [36]. Participants are asked to recall a list of 10 unrelated words across three learning trials, and after a 5-minute delay, they are asked to recall as many words as possible from the list. Total words recalled across the three learning trials were summed to create an immediate recall score. The immediate and delayed recall scores were converted to z-scores using the entire sample’s means and standard deviation at the initial cognitive assessment. An episodic memory composite score was derived as the average of the immediate and delayed recalled z-scores at each visit. Verbal fluency and executive functioning were assessed with tests of letter and semantic fluency. Verbal fluency tests are considered to measure aspects of executive functioning such as organization, initiation and maintenance [37]. Participants were asked to generate as many words that begin with the letter “F” or names of animals in 60 seconds, respectively. Letter and semantic fluency scores were converted to z-scores using the entire sample’s means and standard deviation at the initial cognitive assessment. A verbal fluency composite score was created by averaging the semantic and letter fluency z-scores at each visit. These cognitive measures have been validated for reliable administration over CATI [38, 39].

2.4. Covariates

Covariates included demographic, health behavior, and vascular risk variables collected during the baseline CATI or in-home visit. Demographic covariates included self-reported age, race, and sex, education level, yearly income, and region of residence. Participants reported their education level (< high school, high school degree, some college, ≥ college degree), and yearly income (< $20,000, $20,000–34,000, $35,000–74,000, ≥ $75,000 or unwilling to report). Region was categorized as residence in the stroke belt or non-stroke belt. Health behavior and vascular factors covariates included smoking status, alcohol use, exercise level, diabetes, hyperlipidemia, hypertension, and cardiovascular disease. Smoking status was categorized as never, former or current, and alcohol use as none, moderate (≤ 4 drinks/week for men, ≤ 3 drinks/week for women) or heavy (> 4 drinks on any day or > 14 drinks/week for men, > 3 drinks on any day or > 7 drinks/week for women). Exercise level was categorized as 4 or more times per week, 1 to 3 times per week, and none. Diabetes was defined as fasting glucose ≥ 126 mg/dL, nonfasting glucose ≥ 200 mg/dL, or self-reported use of diabetes medications. Dyslipidemia was defined as total cholesterol ≥ 6.22 mmol/L (240 mg/dL), low density lipoproteins ≥ 4.14 mmol/L (160 mg/dL), high density lipoproteins ≤ 1.04 mmol/L (40 mg/dL) or use of self-reported antihyperlipidemic medications. Hypertension was defined as systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg (average of two blood pressure measurements), or
self-reported use of hypertension medications. Body mass index (BMI) was calculated from height and weight measurements. BMI was computed as kg/m² and categorized according to Centers for Disease Control and Prevention guidelines: underweight (<18.5 kg/m²), normal (18.5–24.9 kg/m²), overweight (25–29.9 kg/m²), or obese (≥30 kg/m²). Prevalent cardiovascular disease was defined as self-reported coronary bypass, percutaneous coronary intervention, myocardial infarction, or myocardial infarction on electrocardiogram.

2.5. Statistical analyses

Descriptive statistics of the sample were calculated in SPSS 26. Longitudinal data were analyzed using latent growth curve models in Mplus version 7 [40] to determine the relationship of CRP to initial levels and rate of change in episodic memory and verbal fluency over time. Time was parametrized as years from baseline. In total, 5 visits (follow-up up to 12 years) were analyzed to maximize covariance coverage. We evaluated model fit by the Bayesian Information Criterion (BIC) [41]. Missing data were managed with full information maximum likelihood using all available data at each occasion. All models included CRP (logCRP or CRP > 90th percentile) as the primary predictor. Initially, separate latent growth curve models were estimated for each cognitive domain (episodic memory, verbal fluency) adjusting only for baseline age. Allowing linear versus curvilinear (age squared) change was compared in each of these models. To assess for evidence of practice effects, a spline modeling retest effects was included [42]. The best fitting models were retained for subsequent analyses that included evaluating the association of CRP and covariates. Compared with models allowing only linear change, fit was improved by allowing both linear and curvilinear change. Fit did not improve by modeling a spline for retest effects for each cognitive domain. Therefore, models estimating retest effects were not used. Subsequently, we built adjusted models in three steps, Step 1 included all demographic covariates, Step 2 added the health behavior covariates, and Step 3 added vascular risk factors. While cardiovascular disease and vascular risk factors (i.e., hypertension, BMI) may be considered mediators between CRP and cognition, we included these covariates in our final models to determine if there was an impact of CRP even after accounting for cardiovascular disease and vascular risk factors. The covariate-adjusted models fit the data well as noted by the improved model fit for each cognitive trajectory as demonstrated by smaller BICs (episodic memory BICs 127001.522, 103072.774; verbal fluency BICs 137901.434, 111822.316).

Multiple-group modeling was used to compare the magnitude of associations between CRP and cognitive trajectory between Black and White people in the unadjusted and adjusted models. Furthermore, given prior studies that report that the association between CRP and cognitive decline is stronger in midlife [19] we conducted post-hoc multiple-group modeling to evaluate whether the association between CRP and cognitive trajectory differed by age groups (midlife < 65 years of age vs late life ≥ 65).

3. Results

Table 1 shows the demographic and health characteristics of the overall sample and by race. Black participants were younger, had lower income, fewer years of education, were more likely to be overweight/obese, and were more likely to have hypertension and diabetes compared to White participants. White participants were more likely to be male and have cardiovascular disease and dyslipidemia. Black participants had higher median CRP than White participants.

3.1. Cognitive trajectories

Table 2 shows the unadjusted and adjusted models for the association of logCRP with episodic memory and verbal fluency. For memory and verbal fluency, higher CRP was associated with...
worse initial scores but not with change over time. After adjusting for covariates (Step 3), there was no independent association of CRP with memory, whereas the association of CRP with baseline verbal fluency remained. Similar patterns were observed when evaluating the association of elevated CRP (>90th percentile; Table 2) on cognitive trajectories. Elevated CRP was associated with worse initial memory and verbal fluency scores but did not influence slope. After adjusting for covariates, the association between elevated CRP and baseline cognition
was partly attenuated, although it remained statistically significant. Multiple group models (Tables 3 and 4) revealed that the association between CRP (both continuous and 90\text{th} percentile status) and cognitive trajectories did not differ reliably by race (all \(p > .05\)).

Post-hoc multiple group models by age group revealed distinct associations between CRP and cognitive trajectories (Table 5). For memory, higher CRP was associated with worse initial scores among participants in midlife compared with older participants, and this interaction remained after adjusting for covariates. There was no association of CRP on memory slope and this did not differ by age group (all \(p > .05\)). For verbal fluency, higher CRP was associated with worse initial scores and this did not differ by age group. There was a counterintuitive association between CRP and change in fluency scores over time such that among older adults

Table 2. Associations of CRP with memory and verbal fluency trajectories.

|                      | logCRP          |                      |                      |
|----------------------|-----------------|---------------------|---------------------|
|                      | Unadjusted Model| Adjusted Model 1    | Adjusted Model 2    | Adjusted Model 3    |
|                      | Initial Level   | Slope               | Initial Level       | Slope               | Initial Level   | Slope               |
| Memory               | -0.039(0.013)** | -0.001(0.002)      | -0.036(0.012)**    | -0.001(0.002)      | -0.027(0.013)  | -0.002(0.002)      | -0.005(0.013)  | -0.001(0.002)          |
| Fluency              | -0.195(0.013)** | -0.04(0.002)*      | -0.077(0.012)**    | -0.002(0.002)      | -0.061(0.012)** | -0.002(0.002)      | -0.042(0.013)** | -0.003(0.002)          |

90\text{th} Percentile CRP

|                      | Unadjusted Model| Adjusted Model 1    | Adjusted Model 2    | Adjusted Model 3    |
|----------------------|-----------------|---------------------|---------------------|---------------------|
|                      | Initial Level   | Slope               | Initial Level       | Slope               | Initial Level   | Slope               |
| Memory               | -0.026(0.022)   | -0.001(0.003)      | -0.077(0.021)**    | -0.001(0.004)      | -0.066(0.021)** | -0.001(0.004)      | -0.045(0.022)* | -0.001(0.004)          |
| Fluency              | -0.132(0.021)** | -0.001(0.003)      | -0.089(0.020)**    | -0.003(0.003)      | -0.071(0.020)** | -0.003(0.003)      | -0.052(0.021)* | -0.003(0.003)          |

Note. Values reflect unstandardized parameter estimates (standard error); adjusted model 1 includes all demographic covariates; adjusted model 2 includes the health behavior covariates; adjusted model 3 added vascular risk factors; \(^* p < .05, \quad ** p < .01, \quad *** p < .001.\) CRP = C reactive protein.

https://doi.org/10.1371/journal.pone.0244612.t002

Table 3. Multiple group comparisons of associations of logCRP with memory and verbal fluency by race.

| Memory | Unadjusted Model | Adjusted Model 1 | Adjusted Model 2 | Adjusted Model 3 |
|--------|------------------|------------------|------------------|------------------|
|        | Intercept        | Slope            | Intercept        | Slope            | Intercept        | Slope            |
| White  | -0.005(0.016)    | -0.001(0.002)    | -0.030(0.015)    | -0.019(0.016)    | -0.003(0.016)    | -0.001(0.003)    |
| Black  | 0.020(0.022)     | 0.002(0.003)     | -0.047(0.021)*   | -0.042(0.022)    | -0.021(0.023)    | -0.001(0.004)    |
| White vs Black | -0.025(0.028) | -0.002(0.004) | 0.017(0.026) | -0.004(0.004) | -0.023(0.027) | -0.001(0.005) | -0.024(0.028) | 0.000(0.005) |

| Verbal Fluency | Unadjusted Model | Adjusted Model 1 | Adjusted Model 2 | Adjusted Model 3 |
|----------------|------------------|------------------|------------------|------------------|
|                | Intercept        | Slope            | Intercept        | Slope            | Intercept        | Slope            |
| White          | -0.155(0.016)**  | 0.002(0.002)     | -0.090(0.016)**  | 0.001(0.002)     | -0.072(0.016)**  | 0.002(0.002)     | -0.055(0.017)**  | 0.003(0.003)     |
| Black          | -0.086(0.019)**  | 0.004(0.003)     | 0.049(0.019)**   | 0.004(0.003)     | 0.037(0.019)     | 0.004(0.003)     | -0.019(0.020)    | 0.005(0.003)     |
| White vs Black | -0.070(0.025)**  | -0.002(0.003)    | -0.041(0.024)    | -0.003(0.004)    | -0.035(0.025)    | -0.002(0.004)    | -0.036(0.026)    | -0.002(0.004)    |

Note. Values reflect unstandardized parameter estimates (standard error); adjusted model 1 includes all demographic covariates; adjusted model 2 includes the health behavior covariates; adjusted model 3 added vascular risk factors; \(^* p < .05, \quad ** p < .01, \quad *** p < .001.\) CRP = C reactive protein.

https://doi.org/10.1371/journal.pone.0244612.t003
higher CRP was associated with greater stability of trajectories, whereas there was no association between CRP and slope among participants in midlife ($p = .02$). The association of CRP with verbal fluency slope by age group was attenuated after adjusting for covariates. None of the previously mentioned results remained when evaluating the association of elevated CRP (>90th percentile; Table 6) on cognitive trajectories.

### 4. Discussion

In this nationally representative, population-based sample of White and Black American adults aged ≥45 years at baseline, higher CRP was associated with worse memory and verbal fluency.
at baseline but not with rate of cognitive decline over a span of 12 years. While the associations of continuous increments of CRP on baseline memory was attenuated after adjusting for demographic and vascular risk factors, the association remained significant among individuals with elevated CRP (>90th percentile). Higher CRP was more consistently associated with worse baseline verbal fluency with and without covariate adjustment. Furthermore, the association of CRP on cognition did not differ by race.

Our large cohort of Black and White adults followed longitudinally allowed us to assess the influence of CRP on cognitive trajectories. While the association of CRP on baseline cognition was robust, our hypothesis that elevated CRP would increase rate of cognitive decline was not supported. There are a few possible explanations for this discrepancy, and our null findings compared to some literature. First, prior studies among older adults that reported an association between CRP and cognitive decline have largely used brief cognitive screeners (i.e., Mini-Mental State Examination) [43], defined cognitive decline based on a single follow-up [16], or had brief follow-up periods (≤10 years) [17]. In contrast, our longitudinal study, focused on discrete cognitive domains (memory, verbal fluency), used measures that were well validated for use in this cohort [38, 39], and leveraged up to 5 follow-ups over the span of 12 years to characterize rate of cognitive decline. Second, previous studies generally accounted for few potentially confounding demographic and health variables. For instance, most studies would only include basic demographics (i.e., age, sex/gender, education) [16, 43, 44], a few others controlled for relevant health behaviors (i.e., alcohol use, smoking) [7, 11] associated with elevated CRP, or medical comorbidities (i.e., cardiovascular disease) [6, 11, 19] that may lie in the casual pathway between inflammation and cognitive decline. Third, we used race-specific cut-offs to determine elevated CRP, which may have influenced results. However, given the variability in CRP concentrations due to genetic ancestry, we believe our approach allows for robust evaluation of CRP across racial/ethnic groups. Moreover, the association between CRP measured continuously on rate of decline did not differ substantially from the associations using cut-offs, which suggests that a different or lower cut-off level for CRP would yield similar null results. As such, given these methodological differences, it may be possible that concentrations of CRP only affect cognitive level and not rate

Table 6. Multiple group comparisons of associations of CRP above the 90th percentile with memory and verbal fluency by age.

|                   | Memory                  | Verbal Fluency          |
|-------------------|-------------------------|-------------------------|
|                   | Intercept               | Slope                   | Intercept               | Slope                   |
| Midlife           | -.102(.027)***          | -.001(.004)             | -.091(.026)**           | -.001(.004)             | -.068(.028)*            |
| Late life         | -.043(.033)             | .000(.006)              | -.033(.034)             | .000(.006)              | -.015(.034)             | -.001(.007)             |
| Midlife vs Late life | -.058(.043)          | .000(.008)              | -.058(.043)             | .000(.008)              | -.053(.044)             | .001(.008)              |
|                   | Intercept               | Slope                   | Intercept               | Slope                   |
| Midlife           | -.098(.027)**           | -.007(.004)             | -.081(.028)**           | -.007(.004)             | -.055(.029)             | -.005(.004)             |
| Late life         | -.081(.030)**           | .003(.005)              | -.064(.030)*            | .003(.005)              | -.056(.030)             | .002(.005)              |
| Midlife vs Late life | -.017(.040)           | -.010(.006)             | -.017(.041)             | -.010(.006)             | .001(.042)              | -.007(.006)             |

Note. Values reflect unstandardized parameter estimates (standard error); adjusted model 1 includes all demographic covariates; adjusted model 2 includes the health behavior covariates; adjusted model 3 added vascular risk factors;
*p < .05,
**p < .01,
***p < .001. CRP = C reactive protein.
of decline among older adults. Fourth, another possible explanation was that the effect of CRP on rate of decline may take place before the age of 65, given various studies suggesting that age-related cognitive decline accelerates during midlife [45], and that higher levels of CRP during midlife are associated with a steeper rate of cognitive decline [19], white matter disease [46, 47], and higher risk of dementia in late-life [6]. While we did not find a faster rate of cognitive decline among participants in midlife in our post-hoc analyses, we did find that among older adults higher CRP was associated with greater stability in verbal fluency trajectories (less decline). Prior studies have reported this inverse relationship between CRP and cognition among older adults, which may be due to successful cognitive aging and survival bias [48, 49]. Differences in mid- and late-life associations were only observed when evaluating CRP continuously but largely attenuated when adjusting for covariates and not present when evaluating individuals with elevated CRP (>90th percentile). Lastly, while we evaluated change in cognition over up to 12 years, this may not be sufficient time to detect cognitive decline, even given our large sample size. For instance, a recent study found an association between midlife CRP and 20-year cognitive decline that was robust to adjustment for multiple covariates [19].

The availability of cognitive data in two domains (episodic memory and verbal fluency) allowed for investigation in domain-specific associations of CRP. Our results indicate that verbal fluency may be more susceptible to the effects of inflammation than episodic memory. Verbal fluency involves skills related to executive functioning (i.e., updating, inhibition) [37, 50] and is associated with integrity of frontal cortical structures, for letter fluency, and frontal and temporal-parietal regions, for semantic fluency [51]. As CRP is considered a marker of vascular disease, these results are in line with research that links vascular risk factors and markers of cerebrovascular disease with impairments in executive functioning [52, 53]. Similarly, a recent study reported that among older adults, higher baseline CRP was associated with reduced blood flow in frontal regions and the anterior cingulate cortex which are both regions associated with executive functioning [54]. Inflammation may lead to impaired endothelial functioning which is associated with white matter hyperintensities [55, 56]. In contrast, while studies have reported an association between elevated levels of CRP and worse performance and declines in episodic memory [19, 57, 58], we only found a robust association with worse memory at CRP levels above the 90th percentile. Inflammation may impact cognition through different mechanisms; it may lead to impaired endothelial functioning which is associated with white matter hyperintensities [55, 56], and with smaller brain volume [59]. Structures important for memory, such as the hippocampus, have high concentrations of pro-inflammatory cytokines and receptors which may be vulnerable to systemic inflammation. Given these domain-specific associations even after adjusting for vascular risk factors and cardiovascular disease, there may be different neurologic pathways through which inflammation may impact cognition.

We did not find that race modified the association between inflammation and cognitive decline. Given prior evidence for race differences in peripheral immune function [25, 26] and studies that have found a stronger association between markers of cerebrovascular disease (i.e., white matter hyperintensities) [53] and metabolic disorders (i.e., diabetes) [60] with cognition among Black compared to White people, we expected to find differences in the relationship between inflammation and cognition by race in the current study. In fact, a recent study from the Health Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study found an association between higher CRP and worse cognitive performance among Black compared to White Americans [61]. However, participants in the HANDLS study were on average in midlife at baseline whereas our sample was older, HANDLS only included 2 cognitive assessments, and the association of CRP with cognition was only found on a test of attention but not on measures of episodic memory or verbal fluency, which mirrors our findings. Moreover, our results are in line with a recent study that did not find race differences in the association
between midlife levels of CRP and cognitive decline in the Atherosclerosis Risk in Communities (ARIC) Study [19]. While the ARIC Study evaluated CRP \( \geq 3 \text{ mg/L} \) [32, 33], we expanded on these results by additionally evaluating CRP using race-specific higher cutoffs (\( \geq 8 \text{ mg/L} \) for White adults and \( \geq 12.3 \text{ mg/L} \) for Black adults) given that CRP levels differ by race due to genetic ancestry [22]. Taken together, most results suggest that among older adults, the association of CRP with cognitive trajectories does not differ by race.

There are several strengths and weaknesses of this study. Strengths include the use of a large, national biracial cohort with serial cognitive assessments in two domains for up to 12 years, the use of structural equation modeling to estimate latent growth curve cognitive trajectories, and the inclusion of potentially confounding demographic and medical factors. A limitation is that it is unknown if findings are generalizable to individuals of other racial/ethnic backgrounds, given that our cohort only included White and Black adults. Another limitation was that given the resource limitations of a large-scale national study, we relied on telephone-based cognitive assessments. Although prior studies have validated telephone administration of cognitive measures and reported that they are comparable to face-to-face evaluations [38, 62], future studies should include a more extensive cognitive battery and in-person evaluations in order to improve sensitivity to cognitive decline. Another limitation is that we measured CRP only once. CRP level can increase in response to injury, infection, and inflammation [9, 63]. Although several studies indicate that CRP \( > 3 \text{ mg/L} \) indicates low grade-inflammation [64], and that CRP plays an important role in systemic inflammation [9], studies have shown that CRP varies within individuals over time and that at least three measurements are required to reliably establish the true mean [65]. It is possible that some participants had acute illness at the time of the CRP measurement, which would bias results towards the null hypothesis. However, the CRP distribution in our cohort was in line with what is expected based on other studies in the United States [66]. In addition, an increase in CRP over time has been associated with cognitive decline in two studies [67, 68], so longitudinal measurement may further help clarify the role of CRP on risk of cognitive impairment. Another similar potential limitation is that we only measured several covariates (i.e., height and weight) at baseline. Like most epidemiologic studies, for reasons of pragmatism, all baseline variables cannot be measured twice, which would improve precision of risk estimates. The impact of this limitation would be a bias to the null hypothesis. Lastly, we did not evaluate the association of CRP in conjunction with other inflammation biomarkers (i.e., IL-6). For instance, a summary index score of inflammation biomarkers including CRP, higher white blood cell counts, and lower serum albumin increased risk prediction of all-cause mortality, even after controlling for various demographic, sociocultural, and medical confounders [69]. Whether similar associations exist for rate of cognitive decline is unknown.

In conclusion, the current study with a large sample size (~20,000 adults) and well-characterized cohort in terms of demographics and medical factors, provides strong evidence that inflammation as measured with CRP at one time point is associated with cognitive level but may not increase rate of cognitive decline among older adults. Based on our findings, CRP may be used as a marker of cognitive impairment among older adults but may not be suitable for risk prediction for early cognitive decline. Further investigations are warranted to disentangle the association of this and other inflammatory markers on cognitive decline from the effects of other demographic and sociocultural risk factors.

**Acknowledgments**

The authors thank the other investigators, staff, and participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at https://www.uab.edu/soph/regardsstudy/.
Author Contributions

Conceptualization: Miguel Arce Rentería, Sarah R. Gillett, Leslie A. McClure, Jennifer J. Manly, Mary Cushman.

Formal analysis: Miguel Arce Rentería, Leslie A. McClure, Jennifer J. Manly.

Funding acquisition: Virginia G. Wadley, Virginia J. Howard, Jennifer J. Manly, Mary Cushman.

Investigation: Leslie A. McClure, Virginia G. Wadley, Virginia J. Howard, Mary Cushman.

Methodology: Miguel Arce Rentería, Virginia G. Wadley, Virginia J. Howard, Mary Cushman.

Writing – original draft: Miguel Arce Rentería, Sarah R. Gillett, Mary Cushman.

Writing – review & editing: Miguel Arce Rentería, Sarah R. Gillett, Leslie A. McClure, Virginia G. Wadley, Stephen P. Glasser, Virginia J. Howard, Brett M. Kissela, Frederick W. Unverzagt, Nancy S. Jenny, Jennifer J. Manly, Mary Cushman.

References

1. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, et al. The public health impact of Alzheimer’s disease, 2000–2050: potential implication of treatment advances. Annual review of public health. 2002; 23:213–31. https://doi.org/10.1146/annurev.publhealth.23.100901.140525 PMID: 11910061

2. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and meta-analysis. Alzheimer’s & dementia: the journal of the Alzheimer’s Association. 2013; 9(1):63–75. e2. https://doi.org/10.1016/j.jalz.2012.11.007 PMID: 23305823

3. Freedman VA, Martin LG, Schoeni RF. Recent trends in disability and functioning among older adults in the United States: a systematic review. Jama. 2002; 288(24):3137–46. https://doi.org/10.1001/jama.288.24.3137 PMID: 12495394

4. Albert SM, Glied S, Andrews H, Stern Y, Mayeux R. Primary care expenditures before the onset of Alzheimer’s disease. Neurology. 2002; 59(4):573–8. https://doi.org/10.1212/01.wnl.59.4.573 PMID: 12196651

5. Li J-Q, Tan L, Wang H-F, Tan M-S, Tan L, Xu W, et al. Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies. J Neurol Neurosurg Psychiatry. 2016; 87(5):476–84. https://doi.org/10.1136/jnnp-2014-310095 PMID: 26001840

6. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia aging study. Annals of neurology. 2002; 52(2):168–74. https://doi.org/10.1002/ana.10265 PMID: 12210786

7. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Archives of neurology. 2004; 61(5):668–72. https://doi.org/10.1001/archneur.61.5.668 PMID: 15148142

8. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Annals of the New York Academy of Sciences. 2010; 1207(1):155–62.

9. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Frontiers in immunology. 2018; 9:754. https://doi.org/10.3389/fimmu.2018.00754 PMID: 29706967

10. Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA. Association of C-reactive protein with cognitive impairment. Archives of neurology. 2010; 67(1):87–92. https://doi.org/10.1001/archneurol.2009.308 PMID: 20685134

11. Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003; 61(1):76–80. https://doi.org/10.1212/01.wnl.0000073620.42047.d7 PMID: 12647160

12. Roberts RO, Geda YE, Knopman DS, Boeve BF, Christianson TJ, Pankratz VS, et al. Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement. 2009; 5(5):398–405. https://doi.org/10.1016/j.jalz.2009.01.025 PMID: 19751919
13. Bahrami A, Bahrami-Taghanaki H, Khorasanchi Z, Tayefi M, Ferns GA, Sadeghnia HR, et al. The Association Between Neuropsychological Function with Serum Vitamins A, D, and E and hs-CRP Concentrations. Journal of Molecular Neuroscience. 2019; 68(2):243–50. https://doi.org/10.1007/s12031-019-01288-x PMID: 30972539

14. Alley DE, Crimmins EM, Karlamangla A, Hu P, Seeman TE. Inflammation and rate of cognitive change in high-functioning older adults. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2008; 63(1):50–5. https://doi.org/10.1093/gerona/63.1.50 PMID: 18245760

15. Weinstein G, Lutskii M, Goldbourt U, Tanne D. C-reactive protein is related to future cognitive impairment and decline in elderly individuals with cardiovascular disease. Archives of gerontology and geriatrics. 2017; 69:31–7. https://doi.org/10.1016/j.archger.2016.11.002 PMID: 27886564

16. Yang J, Fan C, Pan L, Xie M, He Q, Li D, et al. C-reactive protein plays a marginal role in cognitive impairment among older adults in the USA. International journal of geriatric psychiatry. 2016; 31(9):1004–12. https://doi.org/10.1002/gps.4410 PMID: 26766788

17. Shah T, Newcombe P, Smeeth L, Addo J, Casas JP, Whittaker J, et al. Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction. Circulation. 2010; 3(5):436–44. https://doi.org/10.1161/CIRCGENETICS.110.00831 X PMID: 20876875

18. Singh-Manoux A, Dugravot A, Brunner E, Kumari M, Shipley M, Elbaz A, et al. Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. Neurology. 2014; 83(6):486–93. https://doi.org/10.1212/WNL.0000000000000665 PMID: 24991031

19. Walker KA, Gottesman RF, Wu A, Knopman DS, Gross AL, Mosley TH, et al. Systemic inflammation during midlife and cognitive change over 20 years: The ARIC Study. Neurology. 2019; 92(11):e1256–e67. https://doi.org/10.1212/WNL.0000000000007094 PMID: 30760633

20. Wilson RS, Capuano AW, Sytsma J, Bennett DA, Barnes LL. Cognitive aging in older Black and White persons. Psychology and aging. 2015; 30(2):279. https://doi.org/10.1037/pag0000024 PMID: 25961876

21. Diaz-Venegas C, Downer B, Langa KM, Wong R. Racial and ethnic differences in cognitive function among older adults in the USA. International journal of geriatric psychiatry. 2016; 31(9):1004–12. https://doi.org/10.1002/gps.4410 PMID: 26766788

22. Howard VJ, Cushman M, McClure LA, Howard G. Why do we have a stroke belt in the southeastern United States? A review of unlikely and uninvestigated potential causes. The American journal of the medical sciences. 1999; 317(3):160–7. https://doi.org/10.1097/00005650-199903000-00007 PMID: 12218768

23. Callahan CM, Unverzagt FW, Hui SL, Perkins AJ, Hendrie HC. Six-item screener to identify cognitive impairment among potential subjects for clinical research. Medical care. 2002; 40(9):771–81. https://doi.org/10.1097/00005650-200209000-00007 PMID: 15561982

24. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005; 24(3):132–36. https://doi.org/10.1159/000086678 PMID: 15990444

25. Gillett SR, Boyle RH, Zakai NA, McClure LA, Jenny NS, Cushman M. Validating laboratory results in a national observational cohort study without field centers: the Reasons for Geographic and Racial Differences in Stroke cohort. Clin Biochem. 2014; 47(16–17):243–6. https://doi.org/10.1016/j.clinbiochem.2014.08.003 PMID: 25130599

26. Sakkinen PA, Macy EM, Callas PW, Cornell ES, Hayes TE, Kuller LH, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. American journal of epidemiology. 1999; 149(3):261–7. https://doi.org/10.1093/oxfordjournals.aje.a009801 PMID: 9927222
32. Castoldi G, Galimberti S, Riva C, Papagna R, Querci F, Casati M, et al. Association between serum values of C-reactive protein and cytokine production in whole blood of patients with type 2 diabetes. Clinical science. 2007; 113(2):103–8. https://doi.org/10.1042/CS20060338 PMID: 17362204

33. Nyström T. C-reactive protein: a marker or a player? Clinical Science. 2007; 113(2):79–81. https://doi.org/10.1042/CS20070121 PMID: 17447899

34. Evans CR, Long DL, Howard G, McClure LA, Zakai NA, Jenny NS, et al. C-reactive protein and stroke risk in blacks and whites: The REasons for Geographic And Racial Differences in Stroke cohort. American heart journal. 2019; 217:94–100. https://doi.org/10.1016/j.ahj.2019.08.003 PMID: 31520899

35. Gillett SR, Thacker EL, Letter AJ, McClure LA, Wadley VG, Unverzagt FW, et al. Correlates of incident cognitive impairment in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. The Clinical neuropsychologist. 2015; 29(4):466–86. https://doi.org/10.1080/13854046.2015.1042524 PMID: 25978342

36. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989; 39(9):1159–65. https://doi.org/10.1212/wnl.39.9.1159 PMID: 2771064

37. Barry D, Bates ME, Labouvie E. FAS and CFL forms of verbal fluency differ in difficulty: a meta-analytic study. Applied neuropsychology. 2008; 15(2):97–106. https://doi.org/10.1080/09084280802083863 PMID: 18568601

38. Unverzagt FW, Monahan PO, Moser LR, Zhao Q, Carpenter JS, Sledge GW, et al. The Indiana University telephone-based assessment of neuropsychological status: a new method for large scale neuropsychological assessment. Journal of the International Neuropsychological Society. 2007; 13(5):799–806. https://doi.org/10.1017/S1355617707070120 PMID: 17697411

39. Rapp SR, Legault C, Espeland MA, Resnick SM, Hogan PE, Coker LH, et al. Validation of a cognitive assessment battery administered over the telephone. Journal of the American Geriatrics Society. 2012; 60(9):1616–23. https://doi.org/10.1111/j.1532-5415.2012.04111.x PMID: 22985137

40. Muthén L. Mplus user’s guide 7th ed. Los Angeles: Muthén & Muthén; 1998. 2017.

41. Schwarz G. Estimating the dimension of a model. The annals of statistics. 1978; 6(2):461–4.

42. McArdle JJ, Ferrer-Caja E, Hamagami F, Woodcock RW. Comparative longitudinal structural analyses of the growth and decline of multiple intellectual abilities over the life span. Developmental psychology. 2002; 38(1):115. PMID: 11806695

43. Tilvis RS, Kähönen-Väre MH, Jokkonen J, Valvanne J, Piltakala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2004; 59(3):M268–M74. https://doi.org/10.1093/gerona/59.3.m268 PMID: 15031312

44. Teunissen C, Van Boxtel M, Bosma H, Bosmans E, Delanghe J, De Bruijn C, et al. Inflammation markers in relation to cognition in a healthy aging population. Journal of neuroimmunology. 2003; 134(1):142–50.

45. Salthouse TA. Continuity of cognitive change across adulthood. Psychonomic bulletin & review. 2016; 23(3):932–9. https://doi.org/10.3758/s13423-015-0910-8 PMID: 26238759

46. Walker KA, Windham BG, Power MC, Hoogeveen RC, Folsom AR, Ballantyne CM, et al. The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. Neurobiology of aging. 2018; 68:26–33. https://doi.org/10.1016/j.neurobiolaging.2018.03.031 PMID: 29702373

47. Walker KA, Power MC, Hoogeveen RC, Folsom AR, Ballantyne CM, Knopman DS, et al. Midlife systemic inflammation, late-life white matter integrity, and cerebral small vessel disease: the atherosclerosis risk in communities study. Stroke. 2017; 48(12):3196–202. https://doi.org/10.1161/STROKEAHA.117.018675 PMID: 29101255

48. Silverman JM, Beeri MS, Schmeidler J, Rosendorff C, Angelo G, Mavris RS, et al. C-reactive protein and memory function suggest antagonistic pleiotropy in very old nondemented subjects. Age and ageing. 2009; 38(2):237–41. https://doi.org/10.1093/ageing/afn278 PMID: 19147740

49. Silverman JM, Schmeidler J, Beeri MS, Rosendorff C, Sano M, Grossman HT, et al. C-reactive protein and familial risk for dementia: a phenotype for successful cognitive aging. Neurology. 2012; 79(11):1166–23. https://doi.org/10.1212/WMN.0b013e3182698c89 PMID: 22895578

50. Shao Z, Janse E, Visser K, Meyer AS. What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults. Frontiers in psychology. 2014; 5:772. https://doi.org/10.3389/fpsyg.2014.00772 PMID: 25101034

51. Vonk JM, Rizvi B, Lao PJ, Budge M, Manly JJ, Mayeux R, et al. Letter and category fluency performance correlates with distinct patterns of cortical thickness in older adults. Cerebral Cortex. 2019; 29(6):2694–700. https://doi.org/10.1093/cercor/bhy138 PMID: 29893804
52. Vicario A, Martínez CD, Baretto D, Casale AD, Niccoli L. Hypertension and cognitive decline: impact on executive function. The Journal of Clinical Hypertension. 2005; 7(10):598–604. https://doi.org/10.1111/j.1524-6175.2005.00498.x PMID: 16227762

53. B Zahodne L, Manly J, Narkhede A, Y Griffith E, DeCarli C, S Schupf N, et al. Structural MRI predictors of late-life cognition differ across African Americans, Hispanics, and Whites. Current Alzheimer Research. 2015; 12(7):632–9. https://doi.org/10.2174/1567205012666150530203214 PMID: 26027808

54. Warren KN, Beason-Held LL, Carlson O, Egan JM, An Y, Doshi J, et al. Elevated markers of inflammation are associated with longitudinal changes in brain function in older adults. The Journals of Gerontology: Series A. 2018; 73(6):770–8.

55. Hoth KF, Tate DF, Poppas A, Forman DE, Gunstad J, Moser DJ, et al. Endothelial function and white matter hyperintensities in older adults with cardiovascular disease. Stroke. 2007; 38(2):308–12. https://doi.org/10.1161/01.STR.0000254517.04275.3f PMID: 17204686

56. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke. 2005; 36(7):1410–4. https://doi.org/10.1161/01.STR.0000169924.60783.d4 PMID: 15905468

57. Marsland AL, Gianaros PJ, Kuan DC-H, Sheu LK, Krajina K, Manuck SB. Brain morphology links systemic inflammation to cognitive function in midlife adults. Brain, behavior, and immunity. 2015; 48:195–204. https://doi.org/10.1016/j.bbi.2015.03.015 PMID: 25882911

58. Zahodne LB, Kraal AZ, Sharifian N, Zaheed AB, Sol K. Inflammatory mechanisms underlying the effects of everyday discrimination on age-related brain function. Brain, behavior, and immunity. 2019; 75:149–54. https://doi.org/10.1016/j.bbi.2018.10.002 PMID: 30367930

59. Gu Y, Vorburger R, Scarmans N, Luchsinger JA, Manly JJ, Schupf N, et al. Circulating inflammatory biomarkers in relation to brain structural measurements in a non-demented elderly population. Brain, behavior, and immunity. 2017; 65:150–60. https://doi.org/10.1016/j.bbi.2017.04.022 PMID: 28457809

60. Mayeda ER, Karter AJ, Huang ES, Moffet HH, Haan MN, Whitmer RA. Racial/ethnic differences in dementia risk among older type 2 diabetic patients: the diabetes and aging study. Diabetes care. 2014; 37(4):1009–15. https://doi.org/10.2337/dc13-0215 PMID: 22471192

61. Beydoun MA, Dore GA, Canas J-A, Liang H, Beydoun HA, Evans MK, et al. Systemic inflammation is associated with longitudinal changes in cognitive performance among urban adults. Frontiers in aging neuroscience. 2018; 10:313. https://doi.org/10.3389/fnagi.2018.00313 PMID: 30356710

62. Castanho T, Amorim L, Carvalho J, Palha JA, Sousa N, Santos NC. Telephone-based screening tools for mild cognitive impairment and dementia in aging studies: a review of validated instruments. Frontiers in aging neuroscience. 2014; 6:16. https://doi.org/10.3389/fnagi.2014.00016 PMID: 24611046

63. Du Clos TW, Mold C. C-reactive protein. Immunologic research. 2004; 30(3):261–77. https://doi.org/10.1385/IR:30:3:261 PMID: 15531769

64. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. Jama. 2001; 285(19):2481–5. https://doi.org/10.1001/jama.285.19.2481 PMID: 11368701

65. Koenig W, Sund M, Fröhlich M, Löwel H, Hutchinson WL, Pepys MB. Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. American journal of epidemiology. 2003; 158(4):357–64. https://doi.org/10.1093/aje/kwg135 PMID: 12915501

66. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. New England Journal of Medicine. 2006; 352(15):1611–3. https://doi.org/10.1056/NEJM200504143521525 PMID: 15829550

67. Metti AL, Yaffe K, Boudreau RM, Simonsick EM, Carnahan RM, Satterfield S, et al. Trajectories of inflammatory markers and cognitive decline over 10 years. Neurobiology of aging. 2014; 35(12):2785–90. https://doi.org/10.1016/j.neurobiology.2014.05.030 PMID: 24997674

68. Jenny NS, French B, Arnold AM, Strotmeyer ES, Cushman M, Chaves PH, et al. Long-term assessment of inflammation and healthy aging in late life: the Cardiovascular Health Study All Stars. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2012; 67(8):970–6. https://doi.org/10.1093/gerona/gls261 PMID: 22367431

69. Kabagambe EK, Judd SE, Howard VJ, Zakai NA, Jenny NS, Hsieh M, et al. Inflammation biomarkers and risk of all-cause mortality in the reasons for geographic and racial differences in stroke cohort. American journal of epidemiology. 2011; 174(3):284–92. https://doi.org/10.1093/aje/kwr085 PMID: 21685411